An economical and practical procedure of favipiravir synthesis for the treatment of Covid-19

Karataş, Hacer; Hanashalshahaby, Essam Hamied Ahmed; Çatal, Ünal; Bütün, Yaşar Enes; Kurt, Elif; Gürsel, Şahin; Kaya, Adil; Güzel, Mustafa

An economical and practical procedure of favipiravir synthesis for the treatment of Covid-19

dc.authorid	0000-0002-7577-0320
dc.authorid	0000-0002-1423-0435
dc.contributor.author	Karataş, Hacer
dc.contributor.author	Hanashalshahaby, Essam Hamied Ahmed
dc.contributor.author	Çatal, Ünal
dc.contributor.author	Bütün, Yaşar Enes
dc.contributor.author	Kurt, Elif
dc.contributor.author	Gürsel, Şahin
dc.contributor.author	Kaya, Adil
dc.contributor.author	Güzel, Mustafa
dc.date.accessioned	2023-10-05T06:55:10Z
dc.date.available	2023-10-05T06:55:10Z
dc.date.issued	2023
dc.department	İstanbul Medipol Üniversitesi, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümü, Farmasötik Kimya Ana Bilim Dalı
dc.department	İstanbul Medipol Üniversitesi, Rektörlük, Sağlık Bilim ve Teknolojileri Araştırma Enstitüsü
dc.department	İstanbul Medipol Üniversitesi, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümü, Klinik Eczacılık Ana Bilim Dalı
dc.department	İstanbul Medipol Üniversitesi, Sağlık Bilimleri Enstitüsü, Moleküler Tıp ve Biyoteknoloji Ana Bilim Dalı
dc.department	İstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Tıbbi Farmakoloji Ana Bilim Dalı
dc.description.abstract	Favipiravir is a wide-spectrum antiviral generic drug that has received large attention during the recent COVID-19 pandemic. While there are synthetic strategies for favipiravir synthesis, economical procedures could contribute to industrial scale synthesis and availability. Accordingly, our efforts focused on an economic and scalable procedure for favipiravir synthesis via the 3,6-dichloropyrazine-2-carbonitrile intermediate obtained from 3-aminopyrazine-2-carboxylic acid. The process afforded favipiravir with 43% yield (from 3,6-dichloropyrazine-2-carbonitrile, by fluorination, hydroxylation, and nitrile hydrolysis reactions) and greater than 99% purity without a chromatographic purification step. Graphical abstract: [Figure not available: see fulltext.]
dc.description.sponsorship	ATABAY Fine Chemicals and Pharmaceutical Company	en_US
dc.identifier.citation	Karataş, H., Hanashalshahaby, E. H. A., Çatal, Ü., Bütün, Y. E., Kurt, E., Gürsel, Ş. ... Güzel, M. (2023). An economical and practical procedure of favipiravir synthesis for the treatment of Covid-19. Chemical Papers, 77(3), 1695-1702. https://doi.org/10.1007/s11696-022-02595-1
dc.identifier.doi	10.1007/s11696-022-02595-1
dc.identifier.endpage	1702
dc.identifier.issn	0366-6352
dc.identifier.issn	2585-7290
dc.identifier.issue	3
dc.identifier.pmid	36466109
dc.identifier.scopus	2-s2.0-85142345509
dc.identifier.scopusquality	Q2
dc.identifier.startpage	1695
dc.identifier.uri	https://doi.org/10.1007/s11696-022-02595-1
dc.identifier.uri	https://hdl.handle.net/20.500.12511/11522
dc.identifier.volume	77
dc.identifier.wos	000886743800001	en_US
dc.identifier.wosquality	Q3
dc.indekslendigikaynak	Web of Science
dc.indekslendigikaynak	Scopus
dc.indekslendigikaynak	PubMed
dc.institutionauthor	Karataş, Hacer
dc.institutionauthor	Bütün, Yaşar Enes
dc.institutionauthor	Güzel, Mustafa
dc.language.iso	en
dc.publisher	Springer Science and Business Media Deutschland GmbH
dc.relation.ispartof	Chemical Papers	en_US
dc.relation.publicationcategory	Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.relation.tubitak	info:eu-repo/grantAgreement/TUBITAK/SOBAG/18AG020
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	Favipiravir Synthesis
dc.subject	3,6-Dichloropyrazine-2-Carbonitrile
dc.subject	Covid-19 Treatment
dc.subject	Process Development
dc.subject	Active Pharmaceutical Ingredient (API) Synthesis
dc.title	An economical and practical procedure of favipiravir synthesis for the treatment of Covid-19
dc.type	Article